An update on short-course intermittent and prevention therapies for herpes labialis

Herpes

Volumn 14, Issue SUPPL. 1, 2007, Pages

  Gilbert, Stanley ^a   Corey, Lawrence ^b   Cunningham, Anthony ^c   Malkin, Jean Elie ^d   Stanberry, Lawrence ^e   Whitley, Richard ^f   Spruance, Spotswood ^g  

^a Dermatology and Laser Center Northwest   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d INSTITUT PASTEUR   (France)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral; Herpes labialis; Immunomodulation; Prophylaxis; Short course therapy; Steroid

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BEHENYL ALCOHOL; CORTICOSTEROID; FAMCICLOVIR; FLUOCINONIDE; HYDROCORTISONE; IMIQUIMOD; PENCICLOVIR; STEROID; VALACICLOVIR;

BURN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; HERPES LABIALIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOCOMPROMISED PATIENT; INFLAMMATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANTI-INFECTIVE AGENTS, LOCAL; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HERPES LABIALIS; HERPESVIRUS 1, HUMAN; HUMANS; PRACTICE GUIDELINES; RECURRENCE; VIRUS SHEDDING;

HERPES; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 34547798622     PISSN: 09697667     EISSN: 14701537     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother 2002;46:2238-2243.
2. Evans TG, Bernstein DI, Raborn GW. Harmenberg J, Kowalski J, Spruance SL. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrob Agents Chemother 2002;46:1870-1874.
3. Seth AK, Misra A, Umrigar D, Vora N. Role of acyclovir gel in herpes simplex: clinical implications. Med Sci Monit 2003;9:P193-98.
4. Trottet L, Owen H, Holme P, Heylings J, Collin IP, Breen AP et al. Are all aciclovir cream formulations bioequivalent? Int J Pharm 2005;304:63-71.
5. Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA 1997;277:1374-1379.
6. Raborn GW, Martel AY, Lassonde M, Lewis MA, Boon R, Spruance SL; Worldwide Topical Penciclovir Collaborative Study Group. Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials. J Am Dent Assoc 2002;133:303-309.
7. Lin L, Chen XS, Cui PG, Wang JB, Guo ZP, Lu NZ et al. Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial. J Dermatolog Treat 2002;13:67-72.
8. Sacks SL, Thisted RA, Jones TM, Barbarash RA, Mikolich DJ, Ruoff GE et al. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: a multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol 2001;45:222-230.
9. Marcelletti JF. Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs. Antiviral Res 2002;56:153-166.
10. McKeough MB, Spruance SL. Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection. Arch Dermatol 2001;137: 1153-1158.
11. Spruance SL, McKeough MB. Combination treatment with famciclovir and a topical corticosteroid gel versus famciclovir alone for experimental ultraviolet radiation-induced herpes simplex labialis: a pilot study. J Infect Dis 2000;181:1906-1910.
12. Spruance SL, Bodsworth N, Resnick H, Conant M, Oeuvray C, Gao J et al. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 2006;55:47-53.
13. Spruance SL, Rowe NH, Raborn GW, Thibodeau EA, D'Ambrosio JA, Bernstein DI. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: a double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis 1999;179:303- 310.
14. Spruance SL, Jones TM, Blatter MM, Vargas-Cortes M, Barber J, Hill J et al. High-dose, short-duration, early valacyclovir therapy for episodic: treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003;47:1072-1080.
15. Spruance SL, Hill J. Clinical significance of antiviral therapy for episodic-treatment of herpes labialis: exploratory analyses of the combined data from two valaciclovir trials. J Antimicrob Chemother 2004;53:703-707.
16. Laiskonis A, Thune T, Neldam S, Hiltunen-Back E. Valacyclovir in the treatment of facial herpes simplex virus infection. J Infect Dis 2002;186:S66-S70.
17. Chosidow O, Drouault Y, Garraffo R, Veyssier P; Valaciclovir Herpes Facialis Study Group. Valaciclovir as a single dose during prodrome of herpes facialis: a pilot randomized double-blind clinical trial. Br J Dermatol 2003;148:142-146.
18. Spruance SL, Aoki FY, Tyring S, Stanberry L, Whitley R, Hamed, K. Short-course therapy for recurrent genital herpes and herpes labialis. J Fam Practice 2007;56:30-36,
19. Gilbert S. Improving the outcome of facial resurfacing - prevention of herpes simplex virus type 1 reactivation. J Antimicrob Chemother 2001;47:29-34.
20. Rooney JF, Straus SE, Mannix ML, Wohlenberg CR, Ailing DW, Dumois JA et al. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann Intern Med 1993;118:268-272.
21. Baker D, Eisen D. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. Cutis 2003;71:239-242.
22. Gilbert SC. Suppressive therapy versus episodic therapy with oral valacyclovir for recurrent herpes labialis: efficacy and tolerability in an open-label, crossover study. J Drugs Dermatol 2007;6:400-405.
23. Alster TS, Nanni CA. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Dermatol Surg 1999;25:242-246.
24. Wall SH, Ramey SJ, Wall F. Famciclovir as antiviral prophylaxis in laser resurfacing procedures. Plast Reconstr Surg 1999;104:1103-1108.
25. Bisaccia E, Scarborough D. Herpes simplex virus prophylaxis with famciclovir in patients undergoing aesthetic facial CO2 laser resurfacing. Cutis 2003;72:327-328.
26. Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: a randomized clinical trial of dosing regimens. Dermatol Surg 2000;26:50-54.
27. Beeson WH, Rachel JD. Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing. Dermatol Surg 2002;28:331-336.
28. Manuskiatti W, Fitzpatrick RE, Goldman MP, Krejci-Papa N. Prophylactic antibiotics in patients undergoing laser resurfacing of the skin. J Am Acad Dermatol 1999;40:77-84.
29. Alster TS, Nanni CA. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Dermatol Surg 1999;25:242-246.
30. Bernstein DI, Spruance SL, Arora SS, Schroeder JL, Meng TC. Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clin Infect Dis 2005;41:808-814.